Dyadic International (DYAI) Provides Business Update

Dyadic International, Inc. (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, provided an update on its business development efforts related to its Alternative Proteins business and emerging interest in leveraging the C1 platform in the diagnostic and vaccine space to address a variety of infectious diseases, such as the H5N1 Avian Influenza (“Bird Flu”) outbreak. The Company also announced its attendance at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco commencing on January 13, 2025.

“At Dyadic, we remain committed to leveraging our innovative C1 and Dapibus™ protein production platforms to address some of the most pressing challenges in human health, agriculture, and biotechnology,” said Mark Emalfarb, Dyadic’s Chief Executive Officer, “Throughout 2024 our primary focus was on the production and monetization of alternative proteins which has provided a significant and sustainable near-term revenue opportunity for Dyadic. We will maintain that focus through 2025 as our partners prepare for multiple product launches in the Alternative Proteins business. Additionally, over the past several months we have experienced renewed industry interest in leveraging our C1 platform in human and animal health vaccines, and diagnostics. This is highlighted by our recently awarded $3 million grant from the Bill & Melinda Gates Foundation, focused on RSV and Malaria; our collaborations with ViroVax LLC (“ViroVax”) focused on the treatment of monkeypox (“Mpox”) and the diagnosis and treatment of human and avian influenza; and multiple partnerships with innovators seeking to produce infectious diseases antigens in the C1 platform. As we prepare for key product launches and engage with global partners, we are excited about the potential to deliver impactful solutions that address global health.”

Alternative Proteins

Cell Culture Media

• Human Serum Albumin: In partnership with Proliant Health and Biologicals, Dyadic is progressing toward the launch in the first half of 2025 of Human Serum Albumin, a vital cell culture media component that supports cell growth, survival, and function. Additionally, we anticipate achieving a third milestone relating to a productivity threshold (totaling $500,000) during the first half of 2025.
• Transferrin: Recombinant transferrin offers a consistent, animal-free alternative to serum-derived transferrin, reducing variability and contamination risks in pharmaceutical cell culture media. Dyadic is currently in discussions with prospective partners, and providing samples for its recombinant transferrin products, in addition to further analytical and application testing.

Non-Animal Dairy Proteins

• Dairy Enzymes: A recombinant dairy enzyme for cheese production, produced using Dyadic’s Dapibus™ platform, is in the final stages of launch preparation and is expected to debut in 2025. Additional dairy enzymes are under development.
• Alpha-Lactalbumin: Sampling with interested food and reagent companies is underway. Dyadic continues to enhance its alpha-lactalbumin production and evaluate launch strategies for the reagent market.

Reagent Proteins

• DNA-RNA Enzyme Products:
  • C1-produced DNase 1 (RNase-Free) enzyme offering high purity and scalability for molecular diagnostics, biopharma, and other industries.
  • Additionally, Dyadic has developed stable prototypes of four additional DNA/RNA manipulation products including RNase Inhibitors and T7 RNA Polymerase for use in the biopharmaceutical industry.

You May Also Be Interested In

• US Tiger Securities Upgrades Circle Internet Group (CRCL) to Buy, 'anchored in our more constructive view on Bitcoin'
• US power demand to climb through 2027 on data centers, EIA says
• Ipsos names Claire Charbit as head of CEO's office